Iovance Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-2.30 Insider Own0.10% Shs Outstand157.11M Perf Week9.20%
Market Cap1.81B Forward P/E- EPS next Y-2.18 Insider Trans- Shs Float144.23M Perf Month52.74%
Income-358.40M PEG- EPS next Q-0.62 Inst Own99.70% Short Float11.48% Perf Quarter-30.93%
Sales- P/S- EPS this Y-18.90% Inst Trans1.75% Short Ratio3.31 Perf Half Y-37.23%
Book/sh3.51 P/B3.42 EPS next Y11.10% ROA-45.40% Target Price27.23 Perf Year-53.24%
Cash/sh3.19 P/C3.76 EPS next 5Y- ROE-54.80% 52W Range6.18 - 27.96 Perf YTD-37.19%
Dividend- P/FCF- EPS past 5Y-3.80% ROI- 52W High-57.10% Beta0.46
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low94.09% ATR1.03
Employees319 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)60.50 Volatility6.36% 9.43%
OptionableYes Debt/Eq0.00 EPS Q/Q-13.90% Profit Margin- Rel Volume0.50 Prev Close11.99
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume5.00M Price11.99
Recom1.90 SMA2023.92% SMA501.50% SMA200-30.22% Volume154,398 Change0.04%
Jan-28-22Upgrade Stifel Hold → Buy $23 → $25
Dec-07-21Resumed Cowen Outperform
Jun-10-21Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
May-20-21Downgrade Piper Sandler Overweight → Neutral $35 → $18
May-19-21Downgrade Stifel Buy → Hold
May-19-21Downgrade JMP Securities Mkt Outperform → Mkt Perform
May-03-21Initiated Truist Buy $50
Apr-16-21Initiated Goldman Buy $97
Mar-08-21Upgrade H.C. Wainwright Neutral → Buy $50
Dec-15-20Downgrade H.C. Wainwright Buy → Neutral
Oct-06-20Downgrade Wells Fargo Overweight → Equal Weight
Apr-22-20Initiated Mizuho Buy $61
Mar-04-20Initiated Barclays Overweight $45
Feb-26-20Reiterated Oppenheimer Outperform $32 → $35
Feb-26-20Reiterated H.C. Wainwright Buy $32 → $36
Dec-18-19Initiated JMP Securities Mkt Outperform $38
Oct-01-19Initiated Stifel Buy $27
Apr-29-19Initiated Piper Jaffray Overweight $20
Feb-28-19Reiterated Chardan Capital Markets Buy $30 → $20
Feb-07-19Initiated Robert W. Baird Outperform
Jun-22-22 10:48AM  
Jun-17-22 05:15PM  
Jun-13-22 04:01PM  
Jun-12-22 09:00AM  
Jun-08-22 04:01PM  
Jun-06-22 08:34PM  
Jun-05-22 09:06AM  
Jun-03-22 06:52PM  
May-27-22 02:43PM  
May-26-22 04:29PM  
May-20-22 05:15PM  
May-06-22 10:45AM  
May-05-22 04:01PM  
Apr-27-22 04:01PM  
Apr-26-22 07:30AM  
Apr-25-22 04:01PM  
Apr-22-22 05:15PM  
Apr-12-22 04:01PM  
Apr-08-22 03:17PM  
Apr-07-22 04:30PM  
Apr-06-22 12:17PM  
Apr-05-22 04:05PM  
Mar-16-22 11:57AM  
Mar-15-22 05:15PM  
Mar-08-22 04:31PM  
Feb-25-22 09:59AM  
Feb-24-22 04:01PM  
Feb-18-22 05:15PM  
Feb-11-22 04:01PM  
Feb-07-22 12:01AM  
Jan-21-22 05:15PM  
Jan-10-22 08:00AM  
Jan-07-22 04:01PM  
Jan-06-22 05:38PM  
Dec-21-21 06:38PM  
Dec-17-21 05:15PM  
Dec-09-21 02:22PM  
Dec-08-21 07:38PM  
Dec-07-21 08:40AM  
Nov-25-21 11:54AM  
Nov-19-21 05:15PM  
Nov-15-21 10:12AM  
Nov-13-21 04:30PM  
Nov-12-21 01:02PM  
Nov-10-21 09:05AM  
Nov-09-21 08:54AM  
Nov-08-21 04:01PM  
Nov-05-21 07:02AM  
Nov-04-21 04:01PM  
Nov-03-21 07:04AM  
Oct-27-21 09:07AM  
Oct-25-21 04:01PM  
Oct-18-21 04:01PM  
Oct-11-21 11:06AM  
Oct-04-21 10:19PM  
Oct-01-21 08:47AM  
Sep-28-21 05:00PM  
Sep-23-21 07:30AM  
Sep-15-21 04:27PM  
Sep-06-21 01:11PM  
Aug-16-21 08:36AM  
Aug-06-21 09:28AM  
Aug-05-21 04:01PM  
Jul-19-21 04:30PM  
Jul-08-21 02:24AM  
Jun-30-21 10:07AM  
Jun-29-21 03:38PM  
Jun-28-21 07:10PM  
Jun-21-21 05:06AM  
Jun-17-21 07:39AM  
Jun-07-21 08:26AM  
Jun-06-21 09:24AM  
Jun-04-21 09:08AM  
Jun-01-21 07:30AM  
May-25-21 04:47PM  
May-22-21 06:47AM  
May-20-21 04:03PM  
May-19-21 10:52PM  
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Universite de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BILINSKY IGORChief Operating OfficerJun 14Option Exercise0.0018,850018,850Jun 16 05:03 PM
Bellemin Jean-MarcChief Financial OfficerJun 14Option Exercise0.0018,850018,850Jun 16 05:03 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJun 14Option Exercise0.0019,690019,690Jun 16 05:04 PM
Vogt Frederick GInterim CEO & General CounselJun 01Buy6.441,0006,4401,000Jun 02 08:00 PM
Rothbaum Wayne P.DirectorJun 01Buy6.43500,0003,215,5008,067,333Jun 02 07:59 PM
Rothbaum Wayne P.DirectorMay 31Buy6.77500,0003,384,5507,567,333Jun 02 07:59 PM
Maynard Ryan DDirectorMay 31Buy6.757,50050,5887,500Jun 02 08:02 PM
MCPEAK MERRILL ADirectorMay 31Buy6.8010,00068,000218,633Jun 02 08:03 PM
MCPEAK MERRILL ADirectorMay 31Buy6.8410,00068,40020,150Jun 02 08:03 PM
WEISER MICHAELDirectorMay 31Buy6.8010,00067,978112,632Jun 02 08:01 PM